SCHEMBL3547665

SCHEMBL3547665

COC(=O)C1CCN1C(=O)c1cc(OC)c(C)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 1/20 0.51
PDK2 Q15119 2/20 0.47
ALDH1A1 P00352 4/20 0.46
POLB P06746 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
GAA P10253 1/20 0.42
MMP2 P08253 1/20 0.41
ANPEP P15144 1/20 0.41
ROCK2 O75116 1/20 0.41
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
RAB9A P51151 1/20 0.40
PDE4B Q07343 1/20 0.39
PDE4D Q08499 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547667 1.00 FKBP1A (0.51) FKBP1APDK2ALDH1A1POLBTDP1
SCHEMBL3546350 0.89 FKBP1A (0.64) FKBP1APDK2ALDH1A1POLBKMT2A
SCHEMBL3546353 0.89 FKBP1A (0.64) FKBP1APDK2ALDH1A1POLBKMT2A
SCHEMBL3550917 0.86 POLB (0.44) FKBP1AALDH1A1POLBTDP1KMT2A
SCHEMBL3550921 0.86 POLB (0.44) FKBP1AALDH1A1POLBTDP1KMT2A
SCHEMBL3540820 0.85 ALDH1A1 (0.52) FKBP1APDK2ALDH1A1KMT2AROCK2
SCHEMBL3540822 0.85 ALDH1A1 (0.52) FKBP1APDK2ALDH1A1KMT2AROCK2
SCHEMBL3547924 0.84 PDK2 (0.49) FKBP1APDK2ALDH1A1KMT2ARAB9A
SCHEMBL3547926 0.84 PDK2 (0.49) FKBP1APDK2ALDH1A1KMT2ARAB9A
SCHEMBL3544028 0.83 ALDH1A1 (0.49) FKBP1APDK2ALDH1A1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE FKBP1A 3069/4885PDK2 2445/4885ALDH1A1 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.